Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06965621 | 18F-mFBG Imaging for Myocardial Sympathetic Innervation | PHASE2 | NOT YET_RECRUITING | 20 | — | — | Apr 28, 2026 | Dec 30, 2026 | Mar 27, 2026 | 1 | United States |
Obtain computer quantification of global and/or regional differences in myocardial sympathetic innervation (based on 18F-mFBG uptake) between subjects who have and have not experienced an appropriate ICD activation within the previous 12 months
| Arm | Type | Description |
|---|---|---|
| Ischemic cardiomyopathy with ICD discharge | ACTIVE_COMPARATOR | 82Rb and 18F-mFBG will be administered to intraveously to 10 heart failure patients with ischemic cardiomyopathy and an ICD discharge within the past 12 months |
| Ischemic cardiomyopathy without ICD discharge | ACTIVE_COMPARATOR | 82Rb and 18F-mFBG will be administered intravenously to 10 heart failure patients with ischemic cardiomyopathy and no ICD discharge within the past 12 months |
| Name | Type | Description |
|---|---|---|
| 18F-metaFluorobenzylguanidine | DRUG | PET Radiopharmaceutical to assess myocardial sympathetic innervation |
| Rubidium-82 | DRUG | PET Radiopharmaceutical to assess myocardial perfusion |
Inclusion Criteria: * Stable heart failure from ischemic cardiomyopathy, LVEF \< or = 35%, ICD implantation for at least 12 months Exclusion Criteria: * Unstable coronary artery disease, no ICD implantation